



American Society for Experimental NeuroTherapeutics

Advancing neurotherapeutics through collaborations between academia, advocacy, government and industry

November 23, 2016

Dear Member of AUPN,

As past, current and incoming Presidents of the American Society for Experimental NeuroTherapeutics, we are writing to invite you, your faculty colleagues, fellows, and residents to attend **the American Society of Experimental Neurotherapeutics (ASENT) Annual Meeting March 15 through March 17, 2017 at the Hilton Washington DC/Rockville Hotel & Executive Meeting Center in Rockville MD**. In addition to the 2 day Annual Meeting, ASENT is holding its first ever day long course in Clinical Translation on Wednesday March 15, 2017. The course is followed by a dinner symposium, "Careers in Neurotherapeutics". Presenters represent academic clinical neuroscience, the pharmaceutical and device industry, FDA, NIH and neuroscience venture and strategic investment. There is ample opportunity for discussion and networking. **ASENT is pleased to provide free registration to any neurology resident or fellow** for the Clinical Translation course, the Careers in Neuroscience seminar and to the entire annual meeting. In addition, ASENT will provide a **limited number of travel scholarships to trainees** who would not otherwise be able to attend. Trainees will be considered for sponsorship based on available funds and with the recommendation of the Chair or Program Director.

The mission of ASENT and the Society's journal Neurotherapeutics (impact factor 5.054) is to foster the development of neurotherapeutics. ASENT's annual meeting brings together academicians, representatives of the pharmaceutical and device industry, research funding agencies (NINDS, DOD and DARPA), regulators from FDA and representatives of the investment community. The scientific presentations at this meeting are supplemented by active discussion and networking.

As you see in the program agenda, topics at the upcoming ASENT meeting include Alzheimer's disease prevention, biomarkers, therapeutic targets, disease modifying therapies and trial design. A session on Big Data in Neurotherapeutics includes speakers from Verily, the Allen Institute for Brain Science and 23andMe. Other sessions cover pharmacogenomics for CNS medication discovery, the development pipeline, the scientific and regulatory process for dosage determination and prescribing, neuromodulation therapies, drug repurposing, Parkinson's disease (honoring Stan Fahn MD), rapidly acting psychiatric therapeutics, and the placebo effect. Posters and platforms provide an opportunity for attendees to share their research and provide information on therapeutic developments. The program will be of interest for those in academia, industry, and government who are involved in therapeutic development and has broad appeal for trainees and clinicians who want to more deeply understand the background for their daily therapeutic decisions.

Please forward this information to any members of your department who would be interested in attending this meeting, especially your trainees. The meeting program is located at <http://asent.org/annual-meeting/current-annual-meeting/meeting-programa> and information about the Clinical Translation course is at <http://asent.org/events/2017-03-15/clinical-translational-course>.

Sincerely,

Martha J. Morrell MD
President, ASENT
Chief Medical Officer, NeuroPace
Clinical Professor of Neurology and, by
courtesy, Neurosurgery
Stanford University
455 North Bernardo Ave.
Mountain View, CA 94043
mmorrell@neuropace.com
mmorrell@stanford.edu

Thomas Sutula, M.D. Ph.D.
Incoming President, ASENT
Professor of Neurology
University of Wisconsin
Madison, WI 53705
Howard J. Federoff, MD, PhD
Past President, ASENT

Howard J. Federoff, MD, PhD
Past President, ASENT
Vice Chancellor, Health Affairs
CEO, UCI Health System
University of California, Irvine